Table 4.

HPV type-specific results from the MALDI-TOF analysis of 44,146 samples collected during March to November 2008

HPVGendern Positive samples% Positive samples (95% CI)% HPV Positivity restricted to samples with only urine (95% CI)% HPV Positivity restricted to samples with cervicovaginal swabs (95% CI)a
6Women1,3614.1 (3.9–4.3)2.9 (2.6–3.2)4.7 (4.4–5.0)
Men1831.7 (1.5–1.9)1.6 (1.4–1.8)N/A
11Women2890.87 (0.77–0.97)0.65 (0.50–0.80)1.0 (0.87–1.1)
Men480.44 (0.32–0.56)0.37 (0.25–0.49)N/A
16Women3,29810.0 (9.7–10.3)6.6 (6.1–7.1)11.7 (11.3–12.1)
Men2282.1 (1.8–2.4)1.9 (1.6–2.2)N/A
18Women1,6985.1 (4.9–5.3)3.5 (3.2–3.8)6.0 (5.7–6.3)
Men1571.4 (1.2–1.6)1.3 (1.1–1.5)N/A
31Women1,7365.2 (5.0–5.4)3.6 (3.2–4.0)6.1 (5.8–6.4)
Men1471.3 (1.1–1.5)1.2 (0.98–1.4)N/A
33Women7852.4 (2.2–2.6)1.5 (1.3–1.7)2.8 (2.6–3.0)
Men550.50 (0.37–0.63)0.52 (0.38–0.66)N/A
35Women5481.7 (1.6–1.8)1.1 (0.90–1.3)2.0 (1.8–2.2)
Men270.25 (0.16–0.34)0.24 (0.14–0.34)N/A
39Women1,2163.7 (3.5–3.9)2.4 (2.1–2.7)4.3 (4.0–4.6)
Men650.59 (0.45–0.73)0.53 (0.39–0.67)N/A
45Women1,0543.2 (3.0–3.4)2.1 (1.8–2.4)3.7 (3.4–4.0)
Men1010.92 (0.74–1.1)0.72 (0.55–0.89)N/A
51Women1,9846.0 (5.7–6.3)4.2 (3.8–4.6)6.9 (6.6–7.2)
Men1831.7 (1.5–1.9)1.6 (1.4–1.8)N/A
52Women1,5504.7 (4.5–4.9)3.0 (2.7–3.3)5.5 (5.2–5.8)
Men780.71 (0.55–0.87)0.69 (0.53–0.85)N/A
56Women1,3384.0 (3.8–4.2)2.9 (2.6–3.2)4.6 (4.3–4.9)
Men740.67 (0.52–0.82)0.61 (0.46–0.76)N/A
58Women8172.5 (2.3–2.7)1.8 (1.5–2.1)2.9 (2.7–3.1)
Men530.48 (0.35–0.61)0.48 (0.34–0.62)N/A
59Women8592.6 (2.4–2.8)1.9 (1.6–2.2)2.9 (2.7–3.1)
Men440.40 (0.28–0.52)0.31 (0.20–0.42)N/A
66Women1,6815.1 (4.9–5.3)3.6 (3.2–4.0)5.8 (5.5–6.1)
Men1531.4 (1.2–1.6)1.3 (1.1–1.5)N/A
68Women2840.86 (0.76–0.96)0.51 (0.38–0.64)1.0 (0.87–1.1)
Men130.12 (0.055–0.18)0.061 (0.012–0.11)N/A

N/A, not applicable.

  • aSamples combining a cervicovaginal swab with urine are included in this category, as their HPV prevalences were similar to the HPV prevalences in cervicovaginal swabs.